The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells
Abstract
Androgens have been recognized to be primary causative agents of prostate cancer. Following binding to the androgen receptor (AR), androgens serve important roles in the carcinogenesis of prostate cancers. ARs serve an important role during all stages of prostate cancer, and inhibiting their function may help to slow prostate cancer growth. In the present study, the AR gene was targeted in androgen‑positive prostate cancer cells using the clustered regularly interspaced short palindromic repeats‑associated protein (CRISPR/Cas) system. A total of three different single‑guide RNAs (sgRNAs) were designed according to the three different target sites in the AR gene. The optimal sgRNA with a specific target effect was effectively screened to cleave the AR gene in androgen‑positive prostate cancer cell lines, and to suppress the growth of androgen‑sensitive prostate cancer in vitro. The AR‑sgRNA‑guided CRISPR/Cas system was able to disrupt the AR at specific sites and inhibit the growth of androgen‑sensitive prostate cancer cells; further studies demonstrated that the decreased cell proliferation was due to cellular apoptosis. The results of the present study suggested that the CRISPR/Cas system may be a useful therapeutic strategy for the treatment of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The system offers nearly boundless potential to promote progress in combating HIV93, hemophilia94, cancer95, Duchenne muscular dystrophy96, amyotrophic lateral sclerosis97, sickle-cell anemia98, cystic fibrosis99, infertility100, and any number of novel diseases.”
From CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool (2019) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135
Research works printed but not linked: 19
- DeSantis, 2016, Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities, CA Cancer J Clin, 66, 290, 10.3322/caac.21340 · DOI · Paper page
- Feldman, 2001, The development of androgen-independent prostate cancer, Nat Rev Cancer, 1, 34, 10.1038/35094009 · DOI · Paper page
- Saraon, 2011, Molecular alterations during progression of prostate cancer to androgen independence, Clin Chem, 57, 1366, 10.1373/clinchem.2011.165977 · DOI
- Yuan, 2009, Mechanisms mediating androgen receptor reactivation after castration, Urol Oncol, 27, 36, 10.1016/j.urolonc.2008.03.021 · DOI · Paper page
- Cohen, 2009, Mechanisms of prostate cancer cell survival after inhibition of AR expression, J Cell Biochem, 106, 363, 10.1002/jcb.22022 · DOI
- Horii, 2014, Genome engineering using the CRISPR/Cas system, World J Med Genet, 4, 69, 10.5496/wjmg.v4.i3.69 · DOI · Paper page
- Mali, 2013, RNA-guided human genome engineering via Cas9, Science, 339, 823, 10.1126/science.1232033 · DOI · Paper page
- Pu, 2015, Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification, Exp Biol Med (Maywood), 240, 1065, 10.1177/1535370215584932 · DOI
- Seeger, 2014, Targeting hepatitis B virus with CRISPR/Cas9, Mol Ther Nucleic Acids, 3, e216, 10.1038/mtna.2014.68 · DOI · Paper page
- Lu, 2015, Modeling cancer processes with CRISPR-Cas9, Trends Biotechnol, 33, 317, 10.1016/j.tibtech.2015.03.007 · DOI
- Tang, 2016, CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: A personalized molecular surgical therapy, EMBO Mol Med, 8, 83, 10.15252/emmm.201506006 · DOI
- Wang, 2016, CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape, Mol Ther, 24, 522, 10.1038/mt.2016.24 · DOI · Paper page
- Kawamura, 2015, CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells, Oncotarget, 6, 22361, 10.18632/oncotarget.4293 · DOI · Paper page
- Zhang, 2006, Efflux of potassium ion is an important reason of HL-60 cells apoptosis induced by tachyplesin, Acta Pharmacol Sin, 27, 1367, 10.1111/j.1745-7254.2006.00377.x · doi:10.1111/j.1745-7254.2006.00377.x
- Shore, 2014, Management of early-stage prostate cancer, Am J Manag Care, 20, S260
- Yu, 2014, Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells, Onco Targets Ther, 8, 37
- Hu, 2014, Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells, Biomed Res Int 2014, 612823
- Ding, 2013, Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs, Cell Stem Cell, 12, 393, 10.1016/j.stem.2013.03.006 · DOI · Paper page
- Pattanayak, 2014, Determining the specificities of TALENs, Cas9, and other genome editing enzymes, Methods Enzymol, 546, 47, 10.1016/B978-0-12-801185-0.00003-9 · DOI
Cited by
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Metadata
- Authors
- Wei, C., Wang, F., Liu, W., Zhao, W., Yang, Y., Li, K., Xiao, L., & Shen, J.
- Affiliations
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
- Department of Pharmacy, The Affiliated Children's Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
- Center of Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
- Venue
- Molecular Medicine Reports
- Publisher
- Spandidos Publications
- Published
- 2017-12-12
- ISSN
- 1791-2997
- 1791-3004
- PMC
- PMC5783506
- Cited by
- 5
- References
- 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. https://app.cochat.ai/papers/10.3892/mmr.2017.8257
- The paper
- Wei, C., Wang, F., Liu, W., Zhao, W., Yang, Y., Li, K., Xiao, L., & Shen, J. (2017). CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2017.8257
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.